2004/08/31 by Catherine Curran, Neetha Byrappa, Andrew McBride · 321 citations
Medicine · Neuroscience · Psychology · #Acute Psychosis #Antipsychotic #Attention Deficit Hyperactivity Disorder #Clinical psychology #Medicine #Neuroethics, Human Enhancement, Biomedical Innovations #Psychiatry #Psychology #Psychosis #Schizophrenia (object-oriented programming) #Schizophrenia research and treatment #Stimulant
paper · pdf · doi:10.1192/bjp.185.3.196
published in The British Journal of Psychiatry 185(3), 196-204 (Cambridge University Press)
openalex publication_date 2004/08/31 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04
BACKGROUND: Psychosis associated with stimulant use is an increasing problem, but there is little research evidence about the nature of the problem and its management. AIMS: To critically review the literature on stimulant psychosis and sensitisation. METHOD: Systematic review of studies that have investigated stimulant use and psychosis in humans. The main outcome measures were increases in psychosis with stimulant use, and differences between stimulant users and non-users. RESULTS: Fifty-four studies met the inclusion criteria. Experimental studies show that a single dose of a stimulant drug can produce a brief increase in psychosis ratings (a "response") in 50-70% of participants with schizophrenia and pre-existing acute psychotic symptoms, unaffected by the presence of antipsychotic medication. Those with schizophrenia who do not have acute psychotic symptoms respond, but less frequently (30%). There has been little research into the longer-term effects of use. CONCLUSIONS: Compliance with antipsychotic medication by someone with schizophrenia will not prevent a relapse or worsening of psychotic symptoms if stimulants are used. Low-dose antipsychotic treatment may be beneficial in stimulant users, to prevent sensitisation.